Lake Street analyst Thomas Flaten raised the firm’s price target on Optinose to $4 from $3 and keeps a Buy rating on the shares after the company announced the FDA approval of the XHANCE sNDA, which the firm sees opening the door for the company to triple its total addressable market within the specialty segment. However, the firm cautions investors that the timing of the ramp in sales is contingent on payers expeditiously updating their systems to allow claims under the new indication.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OPTN:
- OptiNose trading resumes
- OptiNose Inc: FDA Approval and Future Pediatric Study for XHANCE
- Optinose to resume trading at 4:20 pm ET
- XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
- Optinose says XHANCE nasal spray receives FDA approval
